These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18556452)

  • 1. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy.
    Zeni P; Finger E; Scheinberg MA
    Ann Rheum Dis; 2008 Jul; 67(7):1055-6. PubMed ID: 18556452
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis.
    Hellmann M; Jung N; Owczarczyk K; Hallek M; Rubbert A
    Rheumatology (Oxford); 2008 Jun; 47(6):929-30. PubMed ID: 18411212
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome.
    Kaushik VV; Reddy HV; Bucknall RC
    Ann Rheum Dis; 2006 Aug; 65(8):1116-7. PubMed ID: 16837496
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful use of rituximab for cutaneous vasculitis.
    Chung L; Funke AA; Chakravarty EF; Callen JP; Fiorentino DF
    Arch Dermatol; 2006 Nov; 142(11):1407-10. PubMed ID: 17116830
    [No Abstract]   [Full Text] [Related]  

  • 5. [Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies].
    Grasland A; Crickx B; Blanc M; Pouchot J; Vinceneux P
    Ann Med Interne (Paris); 2000 Sep; 151(5):408-10. PubMed ID: 11033476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Sjogren's syndrome with rituximab.
    Touma Z; Sayad J; Arayssi T
    Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
    [No Abstract]   [Full Text] [Related]  

  • 7. Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome.
    Salama A; Schneider U; Dörner T
    Ann Rheum Dis; 2008 Jun; 67(6):894-5. PubMed ID: 18474659
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.
    Pitarch G; Rodríguez-Serna M; Torrijos A; Oliver V; Fortea JM
    Acta Derm Venereol; 2005; 85(4):374-5. PubMed ID: 16191872
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.
    McGonagle D; Tan AL; Madden J; Rawstron AC; Rehman A; Emery P; Thomas S
    Rheumatology (Oxford); 2008 Apr; 47(4):552-3. PubMed ID: 18281368
    [No Abstract]   [Full Text] [Related]  

  • 10. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical improvement in antiphospholipid syndrome after rituximab therapy.
    Adamson R; Sangle S; Kaul A; Hughes GR; D'Cruz DP
    J Clin Rheumatol; 2008 Dec; 14(6):359-60. PubMed ID: 19033874
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).
    Pagel JM; Lionberger J; Gopal AK; Sabath DE; Loeb K
    Am J Hematol; 2007 Dec; 82(12):1121-2. PubMed ID: 17696200
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment with rituximab of autoimmune haemolytic anaemia causing dialysis-dependent acute renal failure.
    Brown CE; Traynor JP; Sharp RA; Fox JG
    Nephrol Dial Transplant; 2007 Sep; 22(9):2730-1. PubMed ID: 17575312
    [No Abstract]   [Full Text] [Related]  

  • 14. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?
    Zheng WJ; Zhang X; Wang Q; Xu D; Zeng XF; Zhang FC
    Ann Rheum Dis; 2009 Jun; 68(6):1077-8. PubMed ID: 19435726
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of widespread livedoid vasculopathy with pain but no systemic symptoms.
    Okada E; Nagai Y; Ishikawa O
    Acta Derm Venereol; 2008; 88(3):298-9. PubMed ID: 18480943
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy.
    Haroon M; O'Gradaigh D; Foley-Nolan D
    Rheumatology (Oxford); 2007 Apr; 46(4):718-9. PubMed ID: 17289791
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
    Narváez J; Díaz-Torné C; Juanola X; Geli C; Llobet JM; Nolla JM; Díaz-López C
    Ann Rheum Dis; 2009 Apr; 68(4):607-8. PubMed ID: 19286909
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity.
    Tuchinda P; Tammaro A; Gaspari AA
    Arch Dermatol; 2011 Oct; 147(10):1224-5. PubMed ID: 22006147
    [No Abstract]   [Full Text] [Related]  

  • 19. Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin.
    Goerge T; Weishaupt C; Metze D; Nowak-Göttl U; Sunderkötter C; Steinhoff M; Schneider SW
    Arch Dermatol; 2010 Aug; 146(8):927-8. PubMed ID: 20713839
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of rituximab on immunocompetency in patients with autoimmune disease.
    Looney RJ; Srinivasan R; Calabrese LH
    Arthritis Rheum; 2008 Jan; 58(1):5-14. PubMed ID: 18163518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.